⚠ Evidence warning: Clinical trials or other evidence do not support the proposed ways nattokinase lowers blood pressure in people (angiotensin-converting enzyme inhibition, better small-vessel blood flow, blood-vessel lining repair) or the combined reductions described for it alongside lifestyle change. This page keeps it as a report of what people, websites or other media say.

Nattokinase for Blood Pressure

Nattokinase has been studied for blood pressure reduction in two well-conducted randomized controlled trials: the Kim 2008 trial in 86 mildly hypertensive Korean adults (2,000 fibrinolytic units (FU)/day for 8 weeks, average reductions of 5.6 mmHg systolic and 2.8 mmHg diastolic versus placebo) and the Jensen 2016 multicenter North American trial in 79 adults with elevated blood pressure (a significant 3 mmHg fall in diastolic pressure versus placebo; the fall in systolic pressure did not differ significantly from placebo; and a downward trend in von Willebrand factor, a marker of blood-vessel-lining (endothelial) dysfunction and cardiovascular risk, in women only). A 2023 pooled analysis of 6 trials estimated an average fall of about 3.5/2.3 mmHg versus placebo. Two mechanisms are proposed: in laboratory tests, nattokinase-derived peptides have angiotensin-converting enzyme (ACE) inhibitor-like activity (the same enzyme inhibition exploited by pharmaceutical drugs like lisinopril and enalapril), and fibrinolysis-mediated improvement of microcirculation is thought to reduce peripheral vascular resistance independently. The honest summary: a modest effect, described as adjunctive support for prehypertension and stage 1 hypertension alongside lifestyle change, magnesium, potassium-rich diet, and weight management. The trials enrolled people with untreated, mildly raised blood pressure; nattokinase has not been tested as a substitute for prescribed antihypertensives in moderate-to-severe hypertension. In a human study it lowered the clotting factors fibrinogen, factor VII and factor VIII, an effect that adds to that of anticoagulant and antiplatelet drugs (blood thinners).


Table of Contents

  1. The Kim 2008 Randomized Controlled Trial — The Pivotal Hypertension Trial
  2. The Jensen 2016 North American Multicenter Trial
  3. A 2023 Pooled Analysis of the Trials
  4. Mechanism 1: ACE-Inhibitor-Like Activity in Laboratory Tests
  5. Mechanism 2: Microcirculation Improvement via Fibrinolysis
  6. Possible Mechanism 3: A von Willebrand Factor Trend in Women
  7. Magnitude of Effect — What 5/3 mmHg Actually Means
  8. Prehypertension and Stage 1 Hypertension — Where Its Use Is Discussed
  9. Combination with Magnesium, Potassium, and Lifestyle Change
  10. When Nattokinase Is NOT Appropriate for Blood Pressure
  11. Dosing and Time-to-Effect for Blood Pressure
  12. Cautions and Drug Interactions
  13. Key Research Papers
  14. Connections
  15. Featured Videos

The Kim 2008 Randomized Controlled Trial — The Pivotal Hypertension Trial

The Kim 2008 trial published in Hypertension Research is the single most-cited human study supporting nattokinase for blood pressure reduction. Design and results:

Results at 8 weeks:

The Kim trial established the 2,000 FU/day standard dose for blood pressure use, and the 8-week onset-to-significant-effect timeframe. The magnitude of reduction was modest but consistent and clinically meaningful in the mildly-hypertensive population studied.

Back to Table of Contents

The Jensen 2016 North American Multicenter Trial

The Jensen 2016 trial published in Integrated Blood Pressure Control was the first major confirmatory trial in a North American population, addressing one of the principal questions left open by the Kim study (whether the result would replicate outside an East Asian population that consumes substantial dietary natto and soy and may have different baseline cardiovascular risk profiles).

Design and results:

Results:

The Jensen trial partly confirmed the blood pressure-lowering signal in a non-Asian population with relatively low background dietary natto/soy intake: diastolic pressure fell significantly compared with placebo, while the systolic fall did not differ from placebo. Its von Willebrand factor result, a trend in women only, hints at a mechanism beyond simple ACE-inhibitor-like activity but does not establish one.

Back to Table of Contents

A 2023 Pooled Analysis of the Trials

A 2023 systematic review and meta-analysis in Reviews in Cardiovascular Medicine (Li and colleagues) pooled 6 randomized controlled trials with 546 participants. Compared with placebo, nattokinase lowered systolic blood pressure by an average of 3.45 mmHg (95% confidence interval −4.37 to −2.18) and diastolic blood pressure by 2.32 mmHg (−2.72 to −1.92).

The same analysis found some changes in the other direction. Total cholesterol was slightly higher in the nattokinase groups than in the comparison groups, at both lower and higher total doses; at lower total doses, high-density lipoprotein (HDL, "good") cholesterol was a little lower and low-density lipoprotein (LDL) cholesterol a little higher; and blood glucose rose slightly. Triglycerides did not change, and no notable adverse events from nattokinase were reported in any of the trials. The authors concluded that the results support nattokinase as an adjunctive therapy for hypertension, and that more work is needed to learn whether its effects depend on the dose.

Back to Table of Contents

Mechanism 1: ACE-Inhibitor-Like Activity in Laboratory Tests

Angiotensin-converting enzyme is the zinc-metalloprotease that converts angiotensin I to angiotensin II, the principal effector of the renin-angiotensin-aldosterone system (RAAS) and one of the most potent endogenous vasoconstrictors. Angiotensin-converting enzyme inhibitors (lisinopril, enalapril, ramipril, perindopril) are first-line antihypertensive drugs precisely because blocking this enzyme reduces angiotensin II production, lowers vascular tone, reduces aldosterone-mediated sodium retention, and reduces cardiac afterload.

In laboratory (test-tube) tests, nattokinase inhibited angiotensin-converting enzyme (Murakami 2012); the inhibition grew much stronger when heat broke the enzyme apart into small peptides (such as LY and FY), and the authors traced it to those peptides rather than to the enzyme's own protein-cutting action. Beyond this, the fermentation process that produces nattokinase also produces a family of short bioactive peptides with documented ACE-inhibitory activity. These peptides are released by bacterial proteolysis of soy protein during fermentation. The same general phenomenon is well-documented for other fermented foods — the Yamamoto 1994 paper documenting ACE-inhibitory peptides from lactobacillus-fermented milk is a classic example, and there is now substantial literature on antihypertensive peptides from various fermented dairy and soy products.

The ACE inhibition produced by natto-derived peptides is several orders of magnitude weaker than pharmaceutical angiotensin-converting enzyme inhibitors on a molar basis, but the concentrations achieved in the gastrointestinal tract and (to a lesser extent) in plasma after natto consumption are correspondingly higher. Whether this adds up to a meaningful ACE inhibition in people has not been measured directly; the Kim trial measured renin, an earlier step in the same chain, and found it lower with nattokinase.

This mechanism is partially distinct from the fibrinolytic mechanism of nattokinase itself. Some of the ACE-inhibitory effect comes from peptides cut from the nattokinase protein itself, and some is from co-formulated soy-fermentation peptides that may be present in greater or lesser amounts depending on how the supplement was manufactured. Pure nattokinase preparations have less of this effect than less-purified natto-extract products.

Back to Table of Contents

Mechanism 2: Microcirculation Improvement via Fibrinolysis

The second proposed mechanism by which nattokinase may lower blood pressure is fundamentally different from the ACE-inhibitor mechanism: it is thought to work through reduction of peripheral vascular resistance via improved blood rheology rather than through direct effects on the vascular wall.

The chain of logic is:

  1. Nattokinase reduces plasma fibrinogen (~7–10% in the Hsia trial)
  2. Lower fibrinogen reduces whole-blood viscosity (Pais 2006)
  3. Lower fibrinogen also reduces red-cell aggregation at low shear rates, improving microcirculatory perfusion (Pais 2006)
  4. Improved microcirculation at the level of the resistance arterioles and capillaries reduces total peripheral vascular resistance
  5. By the equation blood pressure = cardiac output × total peripheral resistance, reduced total peripheral resistance translates to lower blood pressure at constant cardiac output

This mechanism is a slower-onset, lower-magnitude contributor to blood pressure reduction than the ACE-inhibitor-like activity, but it operates through a fundamentally distinct pathway and the two effects are likely additive rather than redundant. The combined ACE-inhibitor + microcirculation-improvement mechanism is proposed to explain why the magnitude of blood pressure reduction in the Kim trial (~5/3 mmHg) is greater than would be predicted from the ACE-inhibitory activity alone of natto-derived peptides.

For more on the cardiovascular significance of reduced fibrinogen and improved blood rheology, see the cardiovascular and fibrinolysis deep-dive.

Back to Table of Contents

Possible Mechanism 3: A von Willebrand Factor Trend in Women

The Jensen 2016 trial added a finding that was not the primary endpoint but is mechanistically interesting: von Willebrand factor (vWF) decreased among the women taking nattokinase, only as a trend (P < 0.1) that did not reach statistical significance. vWF is a large multimeric glycoprotein produced by endothelial cells and stored in Weibel-Palade bodies; it is released into circulation in response to endothelial activation, inflammation, and shear stress, and serves as a marker of endothelial dysfunction.

Elevated vWF is independently associated with cardiovascular disease risk, particularly thrombotic events. Lowering vWF is not in itself an antihypertensive mechanism, but a lower vWF would reflect improvement in endothelial health, which is a fundamental driver of long-term blood pressure regulation through nitric oxide production, endothelin balance, and prostacyclin synthesis.

The proposed mechanism for a vWF reduction is reduced endothelial inflammation and reduced oxidative stress, secondary to reduced fibrinogen, reduced low-density lipoprotein (LDL) oxidation, and improved microcirculatory perfusion of the endothelium itself. The endothelium is metabolically active tissue and is sensitive to its own perfusion; chronically under-perfused endothelium expresses more vWF, more endothelin, less nitric oxide, all of which raise blood pressure. Whether sustained nattokinase use reverses this cascade has not been tested.

Back to Table of Contents

Magnitude of Effect — What 5/3 mmHg Actually Means

A 5/3 mmHg reduction sounds modest, and at the individual level it often is. But cardiovascular epidemiology has consistently shown that population-level reductions of even 2–3 mmHg in systolic blood pressure translate to clinically meaningful reductions in cardiovascular events. The Prospective Studies Collaboration meta-analysis (61 prospective observational studies, over a million participants) showed that each 2 mmHg reduction in usual systolic blood pressure is associated with approximately 7% lower ischemic heart disease mortality and 10% lower stroke mortality. The 5/3 mmHg reduction seen in the Kim trial would therefore correspond to a roughly 15–20% reduction in projected cardiovascular event risk if sustained.

The key qualifier is "if sustained." The 8-week trial duration of both Kim and Jensen is too short to demonstrate event-rate reductions directly, and no long-term outcome trial of nattokinase has been performed. The benefit is inferred from the established relationship between blood pressure reduction and cardiovascular events that has been documented for pharmaceutical antihypertensives. Whether nattokinase achieves the same cardiovascular benefit per mmHg of blood pressure reduction as an angiotensin-converting enzyme inhibitor or thiazide diuretic is not established; it is plausible based on shared mechanism but is an inference.

Other things are not known either. In the Jensen trial the systolic fall did not differ from placebo. There are only a few short (8-week) trials. And the 2023 pooled estimate (−3.45/−2.32 mmHg) is smaller than the 5/3 mmHg used for the 15–20% projection above, so a projection based on it would be smaller too.

The honest framing for patients: in the Kim trial nattokinase lowered systolic blood pressure by about 5.5 mmHg compared with placebo, and the 2023 pooled analysis estimated about 3.5 mmHg; a 5 mmHg fall is similar to what would be expected from moderate weight loss (~5 kg) or the DASH (Dietary Approaches to Stop Hypertension) diet, and approximately half what would be expected from a low-dose pharmaceutical antihypertensive. It is discussed as one part of a multi-component blood pressure management strategy; the trials did not test it as a standalone substitute for prescription medication in moderate-to-severe hypertension.

Back to Table of Contents

Prehypertension and Stage 1 Hypertension — Where Its Use Is Discussed

The clinical situation in which proponents see the strongest case for nattokinase is the prehypertension (120–129 / <80 mmHg) and stage 1 hypertension (130–139 / 80–89 mmHg) range, where:

Blood pressure stages from normal through prehypertension, stage 1, stage 2 and urgency, with nattokinase’s ideal use case bracketed over prehypertension and stage 1, where a 5/3 mmHg fall can move a reading from borderline elevated into the band below, and marked as not a substitute at 140/90 and above. WHERE NATTOKINASE FITS blood pressure stages in mmHg · bands drawn by stage, not to scale the ideal use case normal prehypertension stage 1 stage 2 urgency 120–129 / <80 130–139 / 80–89 ≥140/90 ≥180/110 −5/3 mmHg borderline elevated → the band below drugs indicated; not a substitute no role THE TYPICAL CANDIDATE 45–65 years old · average BP 130–140 / 82–88 · normal kidneys and coagulation no antithrombotic medication · already losing weight, exercising, cutting sodium 2,000 FU/day for 8–12 weeks WHY HERE drugs often not yet indicated guidelines put lifestyle first a small fall changes the band and long-term risk with it low risk for most if not on anticoagulants or antiplatelet drugs at 140/90 and above it is an adjunct at most, under a physician.

The typical patient profile in which nattokinase is discussed as an addition: a 45–65 year old with average blood pressure in the 130–140 / 82–88 range, no diabetes, normal kidney function, normal coagulation, not on any antithrombotic medication, who is already implementing weight loss, exercise, and dietary sodium reduction and is looking for an additional modality. In this patient nattokinase 2,000 FU/day for 8–12 weeks may produce a clinically meaningful additional 5 mmHg reduction beyond what lifestyle alone achieves.

For more on hypertension itself and its non-pharmaceutical management, see our Hypertension page.

Back to Table of Contents

Combination with Magnesium, Potassium, and Lifestyle Change

Proponents describe nattokinase as most effective when combined with the other established non-pharmaceutical blood pressure interventions. The combinations are mechanistically additive because they work through different pathways:

Ranged bar chart of expected systolic blood pressure reductions: nattokinase about 5 mmHg, magnesium 2 to 4, a potassium-rich diet 3 to 5, a DASH or Mediterranean diet 5 to 11, aerobic exercise 4 to 9 and less alcohol 2 to 4, which together can exceed 15 to 20 mmHg. DIFFERENT PATHWAYS, ADDED TOGETHER expected fall in systolic blood pressure, mmHg · each works a different way 5 mmHg 10 mmHg nattokinase magnesium potassium-rich diet DASH or Mediterranean aerobic exercise less alcohol ~5 2–4 3–5 5–11 4–9 2–4 in deficient subjects in heavier drinkers TOGETHER additive, not redundant enzyme, minerals, diet and exercise act on different levers can exceed 15–20 mmHg in a motivated patient comparable to one drug a single-agent antihypertensive for prehypertension and stage 1 — not stage 2.

The combined effect of nattokinase + magnesium + potassium-rich diet + DASH pattern + exercise can easily exceed 15–20 mmHg systolic reduction in a motivated patient, which is comparable to a single-agent pharmaceutical antihypertensive. This combination strategy is the practical foundation of non-pharmaceutical hypertension management for prehypertension and stage 1 hypertension.

Back to Table of Contents

When Nattokinase Is NOT Appropriate for Blood Pressure

Back to Table of Contents

Dosing and Time-to-Effect for Blood Pressure

Back to Table of Contents

Cautions and Drug Interactions

For more on the broader context of cardiovascular risk reduction, see Hypertension, Atherosclerosis, and Lipid Panel.

Back to Table of Contents

Key Research Papers

  1. Kim JY et al. (2008). Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertension Research 31(8):1583-1588. — PubMed PMID: 18971533
  2. Jensen GS et al. (2016). Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integr Blood Press Control. — PubMed PMID: 27785095
  3. Murakami K, Yamanaka N, Ohnishi K, Fukayama M, Yoshino M (2012). Inhibition of angiotensin I converting enzyme by subtilisin NAT (nattokinase) in natto, a Japanese traditional fermented food. Food Funct. — PubMed PMID: 22453301
  4. Yamamoto N, Akino A, Takano T (1994). Antihypertensive effect of the peptides derived from casein by an extracellular proteinase from Lactobacillus helveticus CP790. J Dairy Sci. — PubMed PMID: 8201050
  5. Hsia CH et al. (2009). Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects. Nutr Res. — PubMed PMID: 19358933
  6. Lewington S et al. (Prospective Studies Collaboration, 2002). Age-specific relevance of usual blood pressure to vascular mortality: meta-analysis of individual data for one million adults. Lancet. — PubMed PMID: 12493255
  7. Sacks FM et al. (DASH-Sodium Collaborative Research Group, 2001). Effects on blood pressure of reduced dietary sodium and the DASH dietary pattern. NEJM. — PubMed PMID: 11136953
  8. Chen H et al. (2018). Nattokinase: a promising alternative in prevention and treatment of cardiovascular diseases. Biomark Insights. — PubMed PMID: 30013308
  9. Li X, Long J, Gao Q, et al. (2023). Nattokinase supplementation and cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. Rev Cardiovasc Med. — PubMed PMID: 39076715

PubMed Topic Searches

  1. PubMed: Nattokinase blood pressure
  2. PubMed: Nattokinase ACE inhibition
  3. PubMed: Nattokinase vWF and endothelial function
  4. PubMed: Natto-derived antihypertensive peptides
  5. PubMed: DASH dietary pattern and BP

Back to Table of Contents

Connections

Back to Table of Contents